cytokine-treated veto cells
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2018 (NCT03622788)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Aplastic · Phase 1/Phase 2
- Bone Marrow Failure Disorders · Phase 1/Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03622788 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2018 | University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1